PowerShares Dynamic Pharmaceuticals (PJP)
This graph shows the price per share over the last few years for an investment fund based on the common stocks of 30 U.S. pharmaceuticals companies. (Top 10 holdings: Johnson & Johnson, Pfizer, Merck, Amgen, Eli Lilly, Bristol-Myers Squibb, Biogen, Gilead Sciences, Depomed, Questcor.) There is over $1 billion invested in this fund.
No, this is not a recommendation to run to your broker and buy these shares; although if you’d like to sell your shares we would not object. We might, however, whisper “blood money” under our breath.
In all seriousness, many people are making huge amounts of money off the pharmaceutical industry. As it was explained to me once by the CEO of a large company in the insurance industry, “We make our money on the misfortunes of others.”
Actually, this would not be such a major issue if it were not for the corrupt alliance between the psychiatric and pharmaceutical industries.
With 30 million Americans having taken antidepressants for a “chemical imbalance” that psychiatrists admit is a pharmaceutical marketing campaign, not scientific fact, it is no wonder that the conflict of interest between psychiatry and Big Pharma perpetuates.
The American Psychiatric Association is steeped in a conflict of
interest with the pharmaceutical industry. After all, it has made at least $40 million just in sales of its Diagnostic and Statistical Manual of Mental Disorders (DSM), often called Diagnosis as a Source of Money, the billing bible that psychiatrists use for insurance reimbursement for “treatment” which is most often psychotropic drugs.
The campaign to “Stop the Stigma” of “Mental Illness” was launched by the Pharmaceutical Industry. With a seemingly altruistic agenda, the fact is the campaign to end the “stigma” of mental illness is one driven and funded by those who benefit from more and more people being labeled mentally ill — pharma, psychiatry and pharmaceutical front groups. The “Founding Sponsors” of the National Alliance on Mental Illness (NAMI) campaign to stop the “stigma” were Abbott Labs, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer, Novartis, SmithKline Beecham and Wyeth-Ayerst Labs.
Controversy swelled around the fifth edition of the DSM, known as DSM-5. One study suggested that the 900-page bible of mental health published in May 2013 is rife with financial conflicts of interest. Nearly 70 percent of DSM-5 task force members reported financial relationships with pharmaceutical companies — up from 57 percent for the previous edition.
St. Louis has not been immune to the fallout from psychiatric drugs. On January 15, 2013, 34-year-old Sean Johnson walked onto the Stevens Institute of Business & Arts campus and shot the school’s financial aid director once in the chest, then shot himself in the torso. Johnson had been taking prescribed drugs for an undisclosed mental illness.
Remember that the real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior or study problems as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax — unscientific, fraudulent and harmful.
It is vital that you, your family and associates watch the video documentary “Making A Killing – The Untold Story of Psychotropic Drugging”. Containing more than 175 interviews with lawyers, mental health experts, the families of psychiatric abuse victims and the survivors themselves, this riveting documentary rips the mask off psychotropic drugging and exposes a brutal but well-entrenched money-making machine. The facts are hard to believe, but fatal to ignore. Watch the video online by clicking here.